These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16720960)

  • 1. Treatment of cognitive impairment in multiple sclerosis.
    Pierson SH; Griffith N
    Behav Neurol; 2006; 17(1):53-67. PubMed ID: 16720960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.
    Bagert B; Camplair P; Bourdette D
    CNS Drugs; 2002; 16(7):445-55. PubMed ID: 12056920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of immunomodulatory treatment on multiple sclerosis fatigue.
    Metz LM; Patten SB; Archibald CJ; Bakker JI; Harris CJ; Patry DG; Bell RB; Yeung M; Murphy WF; Stoian CA; Billesberger K; Tillotson L; Peters S; McGowan D
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1045-7. PubMed ID: 15201369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach.
    Denis L; Namey M; Costello K; Frenette J; Gagnon N; Harris C; Lowden D; McEwan L; Morrison W; Poirier J
    J Neurosci Nurs; 2004 Feb; 36(1):10-22. PubMed ID: 14998102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis.
    Kinsinger SW; Lattie E; Mohr DC
    Neuropsychology; 2010 Sep; 24(5):573-80. PubMed ID: 20804245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 10. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in quality of life in patients with remitted multiple sclerosis during the specific treatment with disease-modifying drugs: a comparative study of populations of Moscow and Novosibirsk].
    Popova EV; Riabukhina OV; Vorob'eva OV; Malkova NA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):67-70. PubMed ID: 21322129
    [No Abstract]   [Full Text] [Related]  

  • 12. Depression in multiple sclerosis: a review.
    Siegert RJ; Abernethy DA
    J Neurol Neurosurg Psychiatry; 2005 Apr; 76(4):469-75. PubMed ID: 15774430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):54-6. PubMed ID: 16252387
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 16. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hungarian validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery and the correlation of cognitive impairment with fatigue and quality of life.
    Sandi D; Rudisch T; Füvesi J; Fricska-Nagy Z; Huszka H; Biernacki T; Langdon DW; Langane É; Vécsei L; Bencsik K
    Mult Scler Relat Disord; 2015 Nov; 4(6):499-504. PubMed ID: 26590654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of telephone-administered cognitive-behavioral therapy on quality of life among patients with multiple sclerosis.
    Cosio D; Jin L; Siddique J; Mohr DC
    Ann Behav Med; 2011 Apr; 41(2):227-34. PubMed ID: 21069585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidance on new therapies in multiple sclerosis patients.
    Gonsette RE
    Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
    [No Abstract]   [Full Text] [Related]  

  • 20. The association between cognitive impairment and quality of life in patients with early multiple sclerosis.
    Glanz BI; Healy BC; Rintell DJ; Jaffin SK; Bakshi R; Weiner HL
    J Neurol Sci; 2010 Mar; 290(1-2):75-9. PubMed ID: 19944429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.